☆ 4.8 Article

Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases

HEPATOLOGY (2019)

期刊

HEPATOLOGY

卷 69, 期 1, 页码 394-419

出版社

WILEY

DOI: 10.1002/hep.30145

关键词

-

类别

Gastroenterology & Hepatology

资金

American Association for the Study of Liver Diseases

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Clinical Neurology

A unique association? A narcolepsy type 1 case comorbid with Primary Biliary Cholangitis

Rosa Peraita-Adrados, Miguel Fernandez-Arquero, Francisco-Javier Martinez-Orozco

Summary: The aim of this study was to report a case of a woman with narcolepsy type 1 co-morbid with asymptomatic primary biliary cholangitis (PBC). The important clinical message of this case is the need to monitor adults with narcolepsy type 1 for late complications associated with other autoimmune conditions. Clinicians should be aware of the relationship between narcolepsy and PBC, and screening and management in these individuals is necessary.

SLEEP MEDICINE (2023)

添加到收藏夹

Article Immunology

The Salivary Microbiota of Patients With Primary Biliary Cholangitis Is Distinctive and Pathogenic

Longxian Lv, Huiyong Jiang, Xiaoxiao Chen, Qiangqiang Wang, Kaicen Wang, Jianzhong Ye, Yating Li, Daiqiong Fang, Yingfeng Lu, Liya Yang, Silan Gu, Jianing Chen, Hongyan Diao, Ren Yan, Lanjuan Li

Summary: The study revealed significant alterations in the salivary microbiota of patients with primary biliary cholangitis (PBC), which may represent a contributing factor to oral inflammation and worsening liver function.

FRONTIERS IN IMMUNOLOGY (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Macrophage Activation Markers Predict Liver-Related Complications in Primary Biliary Cholangitis

Yukihisa Fujinaga, Tadashi Namisaki, Yuki Tsuji, Junya Suzuki, Koji Murata, Soichi Takeda, Hiroaki Takaya, Takashi Inoue, Ryuichi Noguchi, Yuki Fujimoto, Masahide Enomoto, Norihisa Nishimura, Koh Kitagawa, Kosuke Kaji, Hideto Kawaratani, Takemi Akahane, Akira Mitoro, Hitoshi Yoshiji

Summary: Primary biliary cholangitis (PBC) presents with a wide variation in clinical symptoms and course. This study investigated surrogate markers for risk estimation of PBC-related complications and found that serum soluble mannose receptor (sMR) can predict the development of complications in PBC patients. The combination of sMR and soluble CD163 (sCD163) shows better predictive power than sCD163 alone, but the addition of sCD163 does not improve the predictive ability of sMR. These findings contribute to the development of biomarkers for identifying high-risk PBC patients.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Review Immunology

Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?

Yushu Yang, XiaoSong He, Manuel Rojas, Patrick S. C. Leung, Lixia Gao

Summary: Primary biliary cholangitis (PBC) is an immune-mediated liver disease characterized by cholestasis, biliary injuries, liver fibrosis, and chronic non-suppurative cholangitis. The pathogenesis of PBC involves immune dysregulation, abnormal bile metabolism, and progressive fibrosis, leading to cirrhosis and liver failure. Current treatments have limitations, and there is a need for further research to investigate underlying mechanisms and develop more effective therapies.

FRONTIERS IN IMMUNOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Combination antiretroviral therapy improves recurrent primary biliary cholangitis following liver transplantation

Ellina Lytvyak, Mina Niazi, Rohit Pai, Daniel He, Guangzhi Zhang, Stefan G. Hubscher, Andrew L. Mason

Summary: Managment of recurrent primary biliary cholangitis with combination antiretroviral therapy has shown successful outcomes, although it can be associated with side effects.

LIVER INTERNATIONAL (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Liver Transplantation for Primary Biliary Cholangitis

Eric F. Martin

Summary: The number of liver transplantation for primary biliary cholangitis (PBC) has decreased over the years, but it remains an important and curative option for progressive PBC patients. Recent studies from the Global PBC Study Group have provided valuable insights into the changes in PBC before and after liver transplantation.

CLINICS IN LIVER DISEASE (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Obeticholic Acid for Primary Biliary Cholangitis

Annarosa Floreani, Daniela Gabbia, Sara De Martin

Summary: Primary biliary cholangitis (PBC) is a rare autoimmune liver disease with limited treatment options. Ursodeoxycholic acid (UDCA) is the first-line therapy but is ineffective for a significant portion of patients. Obeticholic acid (OCA) is an effective second-line treatment for UDCA-non responders. Future therapies for PBC are promising.

BIOMEDICINES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Secretin alleviates biliary and liver injury during late-stage primary biliary cholangitis via restoration of secretory processes

Lindsey Kennedy, Guido Carpino, Travis Owen, Ludovica Ceci, Debjyoti Kundu, Vik Meadows, Konstantina Kyritsi, Antonio Franchitto, Paolo Onori, Abdulkadir Isidan, Wenjun Zhang, Burcin Ekser, Domenico Alvaro, Eugenio Gaudio, M. Eric Gershwin, Heather Francis, Shannon Glaser, Gianfranco Alpini

Summary: This study investigated the impact of Sct/SR signaling pathway on the biliary secretory processes and injury in late-stage PBC models. The results showed that Sct/SR/CFTR/AE2 expression and bile bicarbonate levels were reduced in late-stage PBC models and human samples. Sct treatment decreased bile duct loss, ductular reaction, inflammation, and fibrosis, and restored the bile acid levels and DCJ structure. The study suggests that Sct treatment may be beneficial for individuals with late-stage PBC.

JOURNAL OF HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis

Atsushi Tanaka, Junko Hirohara, Toshiaki Nakano, Kosuke Matsumoto, Olivier Chazouilleres, Hajime Takikawa, Bettina E. Hansen, Fabrice Carrat, Christophe Corpechot

Summary: The addition of bezafibrate to ursodeoxycholic acid in patients with primary biliary cholangitis was associated with improved prognosis, as evident from a large retrospective cohort study. The combination therapy showed a significant decrease in all-cause and liver-related mortality or need for liver transplantation, indicating the potential benefits of this treatment approach.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: Current Knowledge of Pathogenesis and Therapeutics

Ji-Won Park, Jung-Hee Kim, Sung-Eun Kim, Jang Han Jung, Myoung-Kuk Jang, Sang-Hoon Park, Myung-Seok Lee, Hyoung-Su Kim, Ki Tae Suk, Dong Joon Kim

Summary: Cholangiopathies are various biliary diseases that affect the biliary epithelium and can lead to cholestasis and liver cirrhosis. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are the most important progressive cholangiopathies in adults, with research focusing on genetic risk, epigenetic changes, dysregulated mucosal immunity, and altered biliary epithelial cell function. Understanding the molecular pathogenesis of these diseases can help clinicians prevent and treat them more effectively.

BIOMEDICINES (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Contemporary Epidemiology of Primary Biliary Cholangitis

Francesca Colapietro, Arianna Bertazzoni, Ana Lleo

Summary: The prevalence and incidence trends of PBC have been influenced by improved diagnostic methods and therapeutic options. However, there is a lack of robust epidemiologic data in African regions, South America, and most of South-East nations. Future research should focus on filling this gap and considering the coexistence of metabolic-associated liver disease.

CLINICS IN LIVER DISEASE (2022)

添加到收藏夹

Review Medicine, General & Internal

Risk Stratification in Primary Biliary Cholangitis

Francesco Martini, Daniele Balducci, Martina Mancinelli, Valerio Buzzanca, Elena Fracchia, Giuseppe Tarantino, Antonio Benedetti, Marco Marzioni, Luca Maroni

Summary: Primary Biliary Cholangitis (PBC) is a liver disease with a varied presentation, progression, and response to treatment. Current risk assessment relies on analyzing demographic data, clinical findings, antibody profiles, and liver fibrosis evaluation to identify patients at higher risk of disease progression. The response to therapy after one year remains a significant factor influencing the prognosis of PBC patients. Tailored treatment strategies are emerging to replace the one-size-fits-all approach, requiring the development of risk prediction models to assess patients' course, outcome, and response to treatment at the time of diagnosis. This review provides an overview of current and emerging risk stratification tools and speculates on their potential impact on PBC management.

JOURNAL OF CLINICAL MEDICINE (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

New Treatment Paradigms in Primary Biliary Cholangitis

Cynthia Levy, Michael Manns, Gideon Hirschfield

Summary: Primary biliary cholangitis is an autoimmune disease with symptoms including fatigue, itch, abdominal pain, and sicca complex. Treatment focuses on cholestatic consequences.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Cost of illness of Primary Biliary Cholangitis- a population-based study

Alessio Gerussi, Umberto Restelli, Davide Croce, Marzia Bonfanti, Pietro Invernizzi, Marco Carbone

Summary: This study estimated the economic burden of Primary Biliary Cholangitis (PBC) in Lombardy, Italy, finding that hospitalizations for cirrhosis complications were the main cost driver. Ensuring cost-effective introduction of novel therapies is necessary based on these findings, along with further research on indirect costs such as overall loss of productivity.

DIGESTIVE AND LIVER DISEASE (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis

Christophe Corpechot, Fabrice Carrat, Farid Gaouar, Frederic Chau, Gideon Hirschfield, Aliya Gulamhusein, Aldo J. Montano-Loza, Ellina Lytvyak, Christoph Schramm, Albert Pares, Ignasi Olivas, John E. Eaton, Karim T. Osman, George Dalekos, Nikolaos Gatselis, Frederik Nevens, Nora Cazzagon, Alessandra Zago, Francesco Paolo Russo, Nadir Abbas, Palak Trivedi, Douglas Thorburn, Francesca Saffioti, Laszlo Barkai, Davide Roccarina, Vicenza Calvaruso, Anna Fichera, Adele Delamarre, Esli Medina-Morales, Alan Bonder, Vilas Patwardhan, Cristina Rigamonti, Marco Carbone, Pietro Invernizzi, Laura Cristoferi, Adriaan van der Meer, Rozanne de Veer, Ehud Zigmond, Eyal Yehezkel, Andreas E. Kremer, Ansgar Deibel, Jerome Dumortier, Tony Bruns, Karsten Grosse, Georges-Philippe Pageaux, Aaron Wetten, Jessica Dyson, David Jones, Olivier Chazouilleres, Bettina Hansen, Victor de Ledinghen

Summary: In the largest ever study of LSM in patients with PBC, LSM assessed by VCTE improves prediction of survival beyond biochemical response, established prognostic scores, and age categories, independent of time. LSM can reasonably be regarded as a useful prognostic marker and a potential surrogate endpoint in PBC clinical trials.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC

Michael Trauner, Christopher L. Bowlus, Aliya Gulamhusein, Bilal Hameed, Stephen H. Caldwell, Mitchell L. Shiffman, Charles Landis, Andrew J. Muir, Andrew Billin, Jun Xu, Xiangyu Liu, Xiaomin Lu, Chuhan Chung, Robert P. Myers, Kris V. Kowdley

Summary: In this 96-week open-label extension study, Cilofexor was found to be safe and effective in improving liver function and biomarkers of cholestasis and cellular injury in patients with PSC.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis

Marlyn J. Mayo, Elizabeth Carey, Helen T. Smith, Andrea R. Mospan, Megan McLaughlin, April Thompson, Heather L. Morris, Robert Sandefur, W. Ray Kim, Christopher Bowlus, Cynthia Levy

Summary: This study investigated the impact of pruritus on quality of life and its management in patients with PBC. The prevalence of pruritus was found to be high and it had a negative impact on patients' quality of life. However, the study also found that pruritus in PBC is often undertreated.

DIGESTIVE DISEASES AND SCIENCES (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH

Jun Xu, Ya Wang, Mina Khoshdeli, Matt Peach, Jen-Chieh Chuang, Julie Lin, Wen-Wei Tsai, Sangeetha Mahadevan, Wesley Minto, Lauri Diehl, Ruchi Gupta, Michael Trauner, Keyur Patel, Mazen Noureddin, Kris Kowdley, Aliya Gulamhusein, Christopher L. Bowlus, Ryan S. Huss, Robert P. Myers, Chuhan Chung, Andrew N. Billin

Summary: This study evaluated IL-31 as a potential biomarker for pruritus in clinical trials of cilofexor, an FXR agonist, in patients with cholestatic liver diseases. IL-31 levels were found to be elevated in patients with PSC and PBC and correlated with serum bile acids. The study also showed that cilofexor therapy increased IL-31 levels in patients with NASH.

HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

HCC EV ECG score: An extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma

Na Sun, Ceng Zhang, Yi-Te Lee, Benjamin V. Tran, Jing Wang, Hyoyong Kim, Junseok Lee, Ryan Y. Zhang, Jasmine J. Wang, Junhui Hu, Zhicheng Zhang, Manaf S. Alsudaney, Kuan-Chu Hou, Hubert Tang, Tiffany X. Zhang, Icy Y. Liang, Ziang Zhou, Mengxiang Chen, Angela Hsiao-Jiun Yeh, Wenyuan Li, Xianghong Jasmine Zhou, Helena R. Chang, Steven-Huy B. Han, Saeed Sadeghi, Richard S. Finn, Sammy Saab, Ronald W. Busuttil, Mazen Noureddin, Walid S. Ayoub, Alexander Kuo, Vinay Sundaram, Buraq Al-Ghaieb, Juvelyn Palomique, Kambiz Kosari, Irene K. Kim, Tsuyoshi Todo, Nicholas N. Nissen, Maria Lauda Tomasi, Sungyong You, Edwin M. Posadas, James X. Wu, Madhuri Wadehra, Myung-Shin Sim, Yunfeng Li, Hanlin L. Wang, Samuel W. French, Shelly C. Lu, Lily Wu, Renjun Pei, Li Liang, Ju Dong Yang, Vatche G. Agopian, Hsian-Rong Tseng, Yazhen Zhu

Summary: The study developed an HCC EV-based surface protein assay for early detection of HCC, showing promising potential in detecting early-stage HCC.

HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma

Christopher L. Bowlus, Lionel Arrive, Annika Bergquist, Mark Deneau, Lisa Forman, Sumera I. Ilyas, Keri E. Lunsford, Mercedes Martinez, Gonzalo Sapisochin, Rachna Shroff, James H. Tabibian, David N. Assis

HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus

Cynthia Levy, Stuart Kendrick, Christopher L. Bowlus, Atsushi Tanaka, David Jones, Andreas E. Kremer, Marlyn J. Mayo, Nazneen Haque, Robyn von Maltzahn, Matthew Allinder, Brandon Swift, Megan M. McLaughlin, Gideon M. Hirschfield, GLIMMER Study Grp

Summary: GLIMMER evaluated the dose-response, efficacy, and safety of linerixibat in the treatment of cholestatic pruritus associated with primary biliary cholangitis (PBC). The study found that linerixibat did not show significant difference in itch reduction compared to placebo in the primary intent-to-treat analysis, but it demonstrated a significant dose-dependent reduction in itch in the per protocol population. A well-tolerated dose was identified for Phase 3 investigation in the treatment of cholestatic pruritus in PBC.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

添加到收藏夹

Letter Gastroenterology & Hepatology

Reply: Insurance should cover vancomycin for primary sclerosing cholangitis

Christopher L. Bowlus, Lionel Arrive, Annika Bergquist, Mark Deneau, Lisa Forman, Sumera I. Ilyas, Keri E. Lunsford, Mercedes Martinez, Gonzalo Sapisochin, Rachna Shroff, James H. Tabibian, David N. Assis

HEPATOLOGY (2023)

添加到收藏夹

Letter Gastroenterology & Hepatology

Reply: Living donor liver transplantation for people with PSC

Lisa M. M. Forman, Gonzalo Sapisochin, David N. N. Assis, Lionel Arrive, Annika Bergquist, Christopher L. L. Bowlus, Mark Deneau, Sumera I. I. Ilyas, Keri E. E. Lunsford, Mercedes Martinez, Rachna Shroff, James H. H. Tabibian

HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitis

Michael Trauner, Chuhan Chung, Kate Sterling, Xiangyu Liu, Xiaomin Lu, Jun Xu, Clare Tempany-Afdhal, Zachary D. Goodman, Martti Faerkkilae, Atsushi Tanaka, Palak Trivedi, Kris V. Kowdley, Christopher L. Bowlus, Cynthia Levy, Robert P. Myers

Summary: This article presents the background of PSC and the design and implementation of the phase 3 PRIMIS trial, which aims to evaluate the efficacy and safety of cilofexor in noncirrhotic patients with large-duct PSC. The primary objective is to assess whether cilofexor reduces the risk of fibrosis progression compared with placebo.

BMC GASTROENTEROLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Gideon M. Hirschfield, Mitchell L. Shiffman, Aliya Gulamhusein, Kris Kowdley, John M. Vierling, Cynthia Levy, Andreas E. Kremer, Ehud Zigmond, Pietro Andreone, Stuart C. Gordon, Christopher L. Bowlus, Eric J. Lawitz, Richard J. Aspinall, Daniel S. Pratt, Karina Raikhelson, Maria S. Gonzalez-Huezo, Michael A. Heneghan, Sook-Hyang Jeong, Alma L. Ladron de Guevara, Marlyn J. Mayo, George N. Dalekos, Joost P. H. Drenth, Ewa Janczewska, Barbara A. Leggett, Frederik Nevens, Victor Vargas, Eli Zuckerman, Christophe Corpechot, Eduardo Fassio, Holger Hinrichsen, Pietro Invernizzi, Palak J. Trivedi, Lisa Forman, David E. J. Jones, Stephen D. Ryder, Mark G. Swain, Alexandra Steinberg, Pol F. Boudes, Yun-Jung Choi, Charles A. McWherter

Summary: This study evaluated the efficacy and safety of seladelpar in patients with primary biliary cholangitis who had inadequate response or intolerance to ursodeoxycholic acid. The results showed that seladelpar significantly improved liver biochemistry and pruritus in these patients, and it was well tolerated.

HEPATOLOGY (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Recent Advances in the Management of Primary Sclerosing Cholangitis

David N. Assis, Christopher L. Bowlus

Summary: Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by fibroinflammatory damage to the biliary tree. It is often associated with inflammatory bowel disease and carries an increased risk of liver failure and cholangiocarcinoma. The complexity of the disease and lack of effective therapy have been challenges, but recent advancements in patient characterization, prognostication, and medical management offer hope for progress in the future. This review summarizes current understanding of PSC and highlights areas for further investigation.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2023)

添加到收藏夹

Correction Gastroenterology & Hepatology

Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis (vol 68, 995, 2023)

Marlyn Mayo, Elizabeth T. Carey, Helen R. Smith, Andrea Mospan, Megan McLaughlin, April L. Thompson, Heather Morris, Robert Sandefur, W. Ray Kim, Christopher Bowlus, TARGET PBC Investigators, Cynthia Levy

DIGESTIVE DISEASES AND SCIENCES (2023)

添加到收藏夹

Editorial Material Gastroenterology & Hepatology

Optimizing treatment of primary biliary cholangitis: Is good, good enough?

Christopher L. Bowlus, Cynthia Levy

HEPATOLOGY (2023)

添加到收藏夹

Article Oncology

Biliary Tract Cancers, Version 2.2023 Featured Updates to the NCCN Guidelines

Al B. Benson, Michael I. D'Angelica, Thomas Abrams, Daniel E. Abbott, Aijaz Ahmed, Daniel A. Anaya, Robert Anders, Chandrakanth Are, Melinda Bachini, David Binder, Mitesh Borad, Christopher Bowlus, Daniel Brown, Adam Burgoyne, Jason Castellanos, Prabhleen Chahal, Jordan Cloyd, Anne M. Covey, Evan S. Glazer, William G. Hawkins, Renuka Iyer, Rojymon Jacob, Lawrence Jennings, R. Kate Kelley, Robin Kim, Matthew Levine, Manisha Palta, James O. Park, Steven Raman, Sanjay Reddy, Sean Ronnekleiv-Kelly, Vaibhav Sahai, Gagandeep Singh, Stacey Stein, Anita Turk, Jean-Nicolas Vauthey, Alan P. Venook, Adam Yopp, Nicole McMillian, Ryan Schonfeld, Cindy Hochstetler

Summary: In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into two separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The Biliary Tract Cancers guidelines provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. A multidisciplinary panel of experts meets regularly to review new data and therapies.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2023)

添加到收藏夹

Review Gastroenterology & Hepatology

Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis

Kris. V. V. Kowdley, Christopher. L. L. Bowlus, Cynthia Levy, Marlyn. J. J. Mayo, Daniel. S. S. Pratt, Raj Vuppalanchi, Zobair. M. M. Younossi

Summary: Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune liver disease. There have been recent important developments in the diagnosis, treatment, and monitoring of patients with PBC. In this updated expert consensus document, we provide updates on staging, noninvasive prognostic tools, and a treatment algorithm for clinicians managing PBC.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.